ACM
BBIO icon

AlphaCrest Capital Management’s BridgeBio Pharma BBIO Stock Holding History

AlphaCrest Capital Management’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-19,363
Closed -$323K – 1242
2021
Q4 		$323K Buy
19,363
+10,695
+123% +$452K 0.01% 1238
2021
Q3 		$406K Sell
8,668
-26,293
-75% -$1.41M 0.02% 997
2021
Q2 		$2.13M Buy
34,961
+22,861
+189% +$1.31M 0.09% 342
2021
Q1 		$745K Buy
12,100
+6,300
+109% +$412K 0.04% 622
2020
Q4 		$412K Buy
+5,800
New +$280K 0.03% 765

Other funds holding BBIO

KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
AIG
American International Group New York $609M AUM 23.67% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

AlphaCrest Capital Management's BBIO Position: Q1 2022 in Review

AlphaCrest Capital Management sold out of BridgeBio Pharma (BBIO) in Q1 2022, closing a stake of 19,363 shares — an estimated $323K sold.

AlphaCrest Capital Management first reported a position in BBIO in Q4 2020 and held it in 5 quarters. The position peaked at $2.13M in Q2 2021. 178 funds tracked by Wall St. Rank hold BBIO as of Q1 2022.

  • AlphaCrest Capital Management reported no remaining BridgeBio Pharma position as of Q1 2022 after selling out during the quarter.
  • AlphaCrest Capital Management sold 19,363 BridgeBio Pharma shares in Q1 2022, an estimated $323K.
  • AlphaCrest Capital Management first reported a position in BridgeBio Pharma in Q4 2020 and held it in 5 quarters.
  • AlphaCrest Capital Management's BridgeBio Pharma position peaked at $2.13M in Q2 2021.
  • 178 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2022.

Based on AlphaCrest Capital Management's 13F filing for Q1 2022, filed 12 May 2022.